SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK.

Int J Mol Sci

State Key Laboratory of Biotherapy, Section of Oncogene, West China Hospital, Sichuan University, Chengdu 610041, China.

Published: September 2014

c-Jun N-terminal kinases (JNK) are members of the mitogen-activated protein kinase (MAPK) family that have important roles in signal transduction. The small molecule SP600125 is widely used in biochemical studies as a JNK inhibitor. However, recent studies indicate that SP600125 may also act independent of JNK. Here, we report that SP600125 can induce Src, type I insulin-like growth factor receptor (IGF-IR), Akt and Erk1/2 phosphorylation. Notably, these effects are independent of its inhibition of JNK. Inhibition of Src abrogates the stimulation of IGF-IR, Akt and Erk1/2 phosphorylation. IGF-IR knockdown blunts the induction of both Akt and Erk1/2 phosphorylation by SP600125. Moreover, combination of SP600125 and the Src inhibitor saracatinib synergistically inhibits cell proliferation. We conclude that SP600125 can activate Src-IGF-IR-Akt/Erk1/2 signaling pathways independent of JNK.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200863PMC
http://dx.doi.org/10.3390/ijms150916246DOI Listing

Publication Analysis

Top Keywords

independent jnk
12
akt erk1/2
12
erk1/2 phosphorylation
12
src type
8
igf-ir akt
8
sp600125
7
jnk
6
sp600125 induces
4
src
4
induces src
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!